A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy

Trial Profile

A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2018

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Malignant thymoma; Thymoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2018 Planned End Date changed from 30 Apr 2019 to 30 Apr 2020.
    • 08 Aug 2018 Planned primary completion date changed from 30 Apr 2019 to 30 Apr 2020.
    • 04 May 2018 Planned primary completion date changed from 30 Apr 2018 to 30 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top